On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...
Casita Feliz, a nonprofit serving the Latino LGBTQ+ community in Fresno, recently celebrated its one-year anniversary ...
As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday. The company’s ...
Grace Place: 2024 Haus of Gingerbread Haus of Gingerbread, benefitting the youth of Grace Place, is even bigger and better ...
In Uganda, women and girls are more affected by HIV. Out of 1.4 million people living with the disease, 860 000 are women and ...
Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in ...
Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.
Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...
On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $90.19 which represents a slight increase of $0.43 or 0.48% from the prior close of $89.76. The stock opened at $89 ...
Compared to the aggregate P/E ratio of 94.75 in the Biotechnology industry, Gilead Sciences Inc. has a higher P/E ratio of 1002.11. Shareholders might be inclined to think that Gilead Sciences Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback